In our hands, however, GM-CSF resulted to be mandatory for an efficient anti-tumor response both in vitro and cancer patients (31, 147, 148), while the patient prognosis seemed to be related to systemic inflammation at baseline. This evidence concerns the gene CSF2 and neoplasm.